AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00984295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Tripedia
Description: A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
Study NCT00984295 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Tripedia
Description: A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
Study NCT00984295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Comvax
Description: A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
Study NCT00984295 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Comvax
Description: A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
Study NCT00984295 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Varivax
Description: A single 0.5 mL subcutaneous injection at Day 0
Study NCT00984295 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: M-M-R II
Description: A single 0.5 mL subcutaneous injection at Day 0
Study NCT01737190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP guided by Esophageal pressure + Recruitment maneuver
Description: Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiarory pressure of not more than 5 cm H2O.~A recruitment maneuver with application of 40 cm H2O for up to 40 seconds will be performed.
Study NCT04538170 — intervention group
Intervention type: BEHAVIORAL
Intervention: pain after surgery
Study NCT01072110 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Patients will undergo colonoscopy for evaluation of their symptoms.
Study NCT01072110 — intervention group
Intervention type: PROCEDURE
Intervention: Confocal Laser Endomicroscopy
Description: Patients will undergo CLE during their endoscopy. Findings will be compared to group 1.
Study NCT03605238 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Corticosteroids & tanCART19/20
Description: Twelve days of high-dose IV methylprednisolone (1000mg×3 days, 500mg×3 days, 240mg×3 days, 120mg×3 days) before anti-CD19/20 CAR T cells infusion. The dose is 1E5\~2E6 anti-CD19/20-CAR positive T cells. The cells infusion process may last for 30 min.
Study NCT03185065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: 100 mg of amantadine increased to 200 mg of amantadine, if tolerated
Study NCT03185065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 100 mg of modafinil increased to 200 mg of modafinil, if tolerated
Study NCT03185065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated
Study NCT03185065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: 1 placebo capsule increased to max of 2 capsules twice daily
Study NCT02096419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel dose adjustment
Description: Patients in the interventional arm will receive clopidogrel dose adjustment to maintain optimal platelet reactivity determined by Multiplate function analyzer (19-46U).~They will undergo platelet function testing on day 1,2,3,7,30 and month 2,3,6,9 and 12.~On first two measurements patients will receive up to 2 additional clopidogrel loading doses (600 mg) and put on 150 mg and 75 mg a day if platelet reactivity >18U and \<18U, respectively. Maintenance dose will be determined on following measurements - increased by 75 mg if >46U; not changed if 19-46U; decreased by 75 mg if \<19U. Minimal dose - 75 mg; maximal dose 300 mg (for patients >70 years 150 mg)
Study NCT00728949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12 (cixutumumab)
Description: 10 mg/kg I.V.
Study NCT00728949 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IMC-A12 (cixutumumab)
Description: 10 mg/kg I.V.
Study NCT00728949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen
Description: Daily 20 mg, oral
Study NCT00728949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Daily 1 mg, oral
Study NCT00728949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Daily 2.5 mg, oral
Study NCT00728949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Daily 25 mg, oral
Study NCT00728949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Monthly 250 mg, intramuscularly
Study NCT03408626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Papain-based Chemo-mechanical caries removal agent
Description: Birx 3000 and the exclusive Encapsulating Buffer Emulsifier (EBE) technology claim it has effective and selective proteolytic action to remove collagen fiber in the carious tissue. It has an antibacterial and antifungal power, thus it has an antiseptic power at the tissue level .furthermore, this gel does not contain chloramines in its formula, which enhances its toxicological safety feature.
Study NCT03408626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papain-based Chemo-mechanical caries removal agent
Description: Birx 3000 and the exclusive Encapsulating Buffer Emulsifier (EBE) technology claim it has effective and selective proteolytic action to remove collagen fiber in the carious tissue. It has an antibacterial and antifungal power, thus it has an antiseptic power at the tissue level .furthermore, this gel does not contain chloramines in its formula, which enhances its toxicological safety feature.
Study NCT03408626 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: conventional rotary
Description: traditional rotary method
Study NCT03408626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional rotary
Description: traditional rotary method
Study NCT04978532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: The children in the guided imagery group listened to a voice recording named 'Stroll in the Forest' before and during venipuncture. One minute before venipuncture, children wore an earphone and voice recording started. Children closed their eyes, imagined the text content, and focused on the voice recording while listening to the voice. It is a voice recording that helps the children in the guided imagery group to imagine that they are strolling in a forest and guides them.
Study NCT04978532 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: No intervention was made in the children.
Study NCT02433678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapagliflozin
Description: SGLT-2 inhibitor for the treatment of type 2 diabetes
Study NCT02433678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04605107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epifasi: Human chorionic gonadotrophin
Description: IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin
Study NCT04605107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnyl: Human chorionic gonadotrophin
Description: IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin
Study NCT04084483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-161
Description: K-161 alternate dosage
Study NCT04084483 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle)
Description: Placebo solution
Study NCT02827409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short Delay Cord Clamping
Description: Delay cord clamping will occur for up to 1 minute. Subject will be placed on mother's abdomen for warmth and stimulation. If the subject is depressed they will be transferred to the radiant warmer for resuscitation.
Study NCT02827409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extended Delay Cord Clamping
Description: Extended delay cord clamping will occur for at least 5 minutes and will continue until the subjects begins breathing and/or the cord stops pulsating. Subject will be placed on mother's abdomen for warmth and stimulation. If the subject is depressed they will be transferred to the LifeStart bed for resuscitation adjacent to the mother's bedside.
Study NCT03797664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-6114
Description: CDX-6114 will be administered as a single, oral dose solution at dose levels of 7.5, 15.0 and 22.5g
Study NCT03797664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate Buffer Diluent oral solution
Study NCT00726960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: Oral, 125 mg once daily for one week
Study NCT00726960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pseudo-placebo - buprenorphine
Description: Randomized to receive either 8 mg sublingual tablets or 0.4 mg sublingual tablets
Study NCT00982553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 800mg once daily
Study NCT00982553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400mg twice daily
Study NCT01362998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preservative free morphine
Description: 3mg given epidurally during the Cesarean section.
Study NCT01362998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: An infusion of epidural fentanyl started during the Cesarean section. It will be given on a patient controlled analgesia basis, with a basal rate of 60 micrograms, a demand dose of 16 micrograms, and a lockout of 15 mins.
Study NCT00727571 — intervention group
Intervention type: OTHER
Intervention: Observations
Description: This is a non-interventional, observational study; no investigational product is being used
Study NCT03682900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Click City®: Tobacco
Description: A computer-based program assigned to students designed to prevent subsequent tobacco use. Students complete one 15 to 20 minute lesson two times a week for four weeks.
Study NCT03682900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Tobacco Curriculum
Description: Students complete their usual curriculum designed to prevent tobacco use.
Study NCT01684553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow eating condition
Description: The subjects were asked to eat their meal slowly during the slow eating condition
Study NCT01684553 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fast eating condition
Description: The subjects were asked to eat their meal quickly during the fast eating condition
Study NCT00583895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
Study NCT04724993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Aerobic Dance Exercises
Description: Online aerobic dance exercises will be performed with observance of physiotherapist. They will record their daily physical activity.
Study NCT01261078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intrathecal 8 mg of bupivacaine only
Study NCT01261078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine 25
Description: intrathecal 8 mg of bupivacaine mixed with 25 mcg of epinephrine
Study NCT01261078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine 50
Description: intrathecal 8 mg of bupivacaine mixed with 50 mcg of epinephrine
Study NCT01261078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine 100
Description: intrathecal 8 mg of bupivacaine mixed with 0.1 mg of epinephrine
Study NCT01261078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epi 200
Description: intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
Study NCT01199861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Fingolimod 0.5 mg capsules for oral administration.
Study NCT01199861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules for oral administration.
Study NCT01199861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine
Description: Commercially available injectable influenza vaccine for the 2010/11 influenza season.
Study NCT01199861 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Seasonal influenza vaccine
Description: Commercially available injectable influenza vaccine for the 2010/11 influenza season.
Study NCT01199861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid vaccine
Description: Commercially available tetanus toxoid vaccine booster injection.
Study NCT04724993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Counseling
Description: Physical activity and exercise will ve explained to the participants.And they will record their daily physical activity.
Study NCT03638765 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVax-Direct
Description: activated, autologous dendritic cells
Study NCT01199861 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tetanus toxoid vaccine
Description: Commercially available tetanus toxoid vaccine booster injection.
Study NCT00954915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: teplizumab
Description: Cohorts 1-5: escalating doses of subcutaneously administered teplizumab; cohort 6: intravenous administration of maximum tolerated subcutaneous dose.
Study NCT02227862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylan's insulin glargine
Description: All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period, and will continue on this for the complete trial. During the 6 week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
Study NCT02227862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus®
Description: All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period; and will continue on this for the complete trial. During the 6week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
Study NCT04545762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given intravenously (IV)
Study NCT04545762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously (IV)
Study NCT04545762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR-T cells
Description: Single infusion
Study NCT00005842 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Study NCT00005842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Study NCT01919190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL
Description: TAP with EXPAREL
Study NCT01919190 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01977469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low intensity resistance training
Description: The LIRT group initiated the resistance training for UL with 30% of the 1RM, with 5% increases each nine sessions; therefore, the maximum load was 45% of the 1RM. The LL training initiated with 30% of the 1RM, increasing 7% each nine sessions, thus, the maximum load was 51% of the 1RM. Each exercise session consisted of three sets of 15 repetitions, with a 2 minutes interval between sets.
Study NCT01977469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity resistance training
Description: the initial load for HIRT group was 60% of 1RM for UL with 5% increases each nine sessions; therefore, the maximum load reached 75% of the 1RM. The LL training initiated with 60% of the 1RM with 7% increments each nine sessions, as a result, the maximum load after 36 sessions was 81% of the 1RM. These patients underwent three sets of eight repetitions, with two minutes intervals between sets.
Study NCT01977469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Patients underwent an aerobic training in cycle ergometer, with load intensity determined as the same load the patient presented a VO2 value of 70-80% of the peak VO2 obtained in the symptom-limited CPET. Each session of aerobic training lasted 20-30min according to patient's tolerance.
Study NCT03489759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViE15-A
Description: The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be ViE15-A.
Study NCT03489759 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: REXEED-15A
Description: The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be REXEED-15A.
Study NCT02297451 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal radial/ulnar artery as inflow
Description: Proximal radial/ulnar artery used as inflow
Study NCT00643877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative hepatic and regional arterial chemotherapy using oxaliplatin, MMC and FUDR
Description: PHRAC which included of two parts(common hepatic artery chemotherapy and main tumor supplying artery chemotherapy) was performed 7 days before surgery： common hepatic artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg main tumor supplying artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg
Study NCT00643877 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: surgery
Description: radical surgery only
Study NCT02840409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine
Study NCT02840409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Study NCT02840409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT00929539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-130
Description: Tablets
Study NCT00929539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JTT-130 Placebo
Description: Tablets
Study NCT01106326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Teens participating in this study will have:~1. directly observed administration of their daily preventive asthma medication at school, by the school nurse, for the first 6-8 weeks of the study~2. three counseling sessions with a study nurse trained in principles of motivational interviewing (MI), that are designed to enhance the teen's motivation to change health behaviors, with a focus on adherence to evidence-based preventive care guidelines (e.g.; preventive medications).
Study NCT01512407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolisation using cisplatin-lipiodol mixture
Description: Cisplatin-lipiodol mixture was infused through catheter placed at hepatic artery followed by gelfoam embolisation. This is performed 4 to 6 weeks after surgery
Study NCT02607319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemiparin sodium
Description: Bemiparin sodium 3,500 IU will be started on the evening of the same day of embryo transfer and until the day of pregnancy test. If the test is positive, Bemiparin will be discontinued by the end of the 12th week of gestation.
Study NCT01144936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-985 or matching placebo
Description: low dose
Study NCT01144936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-985 or matching placebo
Description: high dose
Study NCT01144936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-985 or matching placebo
Description: dose TBD
Study NCT01341366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast-track perioperative program
Description: Preoperative counseling, no preoperative fasting, short-acting anesthetics, continuous infiltration of wound with local anesthetic agent, non-opioid pain management, the use of chewing gum, and early postoperative feeding and mobilization
Study NCT01341366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional perioperative program
Description: Preoperative fasting, standard anesthetic management with no intraoperative fluid restriction, opioid pain management, no chewing gum, feeding/mobilization according to attending surgeon